The FDA just approved an updated COVID vaccine for the 2026–27 season — shipping has begun

The US Food and Drug Administration has approved Pfizer and BioNTech's updated COVID-19 vaccine for the 2026–2027 season, formulated against the XFG variant the FDA identified as the preferred composition for this autumn. The approval covers adults aged 65 and over, and people aged 5 to 64 with at least one underlying condition that raises their risk of severe illness. It rests on the companies' body of clinical, nonclinical and real-world evidence, plus data showing the updated formula generates strong immune responses against currently circulating variants. Shipping began immediately, with availability expected at pharmacies, hospitals and clinics in the coming days.

SDG 3 · Good health and well-being — Mechanism: policy reform